{
    "clinical_study": {
        "@rank": "117746", 
        "arm_group": [
            {
                "arm_group_label": "7500 TSO", 
                "arm_group_type": "Active Comparator", 
                "description": "7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks"
            }, 
            {
                "arm_group_label": "15000 TSO", 
                "arm_group_type": "Active Comparator", 
                "description": "15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks"
            }, 
            {
                "arm_group_label": "Non-active treatment", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, blinded, multicenter study to assess the safety and treatment effect\n      of 12 weeks of Trichuris suis ova  in subjects diagnosed with moderate to severe chronic\n      plaque psoriasis."
        }, 
        "brief_title": "TSO for Plaque Psoriasis", 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, 18 to 75 years old.\n\n          -  Diagnosis of stable plaque type psoriasis for at least 6 months prior to baseline\n\n          -  Baseline moderate to severe psoriasis, defined as both of the following:\n\n               1. Psoriasis covering a body surface area (BSA) \u2265 10%, and;\n\n               2. PGA \u2265 3, and;\n\n               3. PASI \u2265 12\n\n        Exclusion Criteria:\n\n          -  Patients who are currently taking or have taken in the past 30 days, for any reason,\n             any medication that, in the opinion of the investigator, suppressed the immune\n             response. This may include but is not limited to systemic steroids, azathioprine,\n             methotrexate, cyclosporine, FK506, mycophenolate mofetil, mycophenolic acid,\n             etanercept, adalimumab, infliximab, ustekinumab, cimzia, or any other biologic agent\n             targeted to any cell or cytokine in the immune system.  Patients who are on inhaled\n             or ophthalmic steroids are allowed.\n\n          -  Patients who have demonstrated a primary lack of response to any one of the following\n             biologic agents: etanercept, adalimumab, infliximab or ustekinumab. Patients who\n             initially responded to one of these agents but subsequently lost response (secondary\n             lack of response) are eligible for study entry; however, secondary lack of response\n             to more than one of these agents will exclude the patient from study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011269", 
            "org_study_id": "CNDO 201-201", 
            "secondary_id": "CNDO 201-201"
        }, 
        "intervention": {
            "arm_group_label": [
                "7500 TSO", 
                "15000 TSO", 
                "Non-active treatment"
            ], 
            "intervention_name": "Trichuris Suis Ova", 
            "intervention_type": "Biological", 
            "other_name": "TSO"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "TSO", 
            "Ova", 
            "Psoriasis", 
            "plaque psoriasis", 
            "plaque-type", 
            "Coronado", 
            "Moderate to severe plaque psoriasis"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Blinded, Placebo-controlled Multicenter Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis", 
        "overall_contact": {
            "email": "mryan@coronadobio.com", 
            "last_name": "Michael Ryan"
        }, 
        "overall_contact_backup": {
            "email": "awheeler@coronadobio.com", 
            "last_name": "Amy Wheeler"
        }, 
        "overall_official": {
            "affiliation": "Coronado Biosciences", 
            "last_name": "Michael Ryan", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean percent change in Psoriasis Area and Severity Index (PASI) score from pre-treatment at Week 0 to Week 12", 
            "measure": "Mean percent change in Psoriasis Area and Severity Index (PASI) score", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011269"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Coronado Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Coronado Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}